Table 1.
Novel ocular antihypertensive compounds in established pharmacologic classes
| Drug class/Compound | Organization | Highest development phase | Notes |
|---|---|---|---|
| β-Adrenergic blocker | |||
| SYL040012 | Zeltia/Sylentis | PI/II | β2-adrenergic antagonist – siRNA |
| Prostaglandin analogs | |||
| AR-102; mopidamol | Aerie | PII | FP agonist |
| BOL-303259-X; NCX-116; PF-03187207 | NicOx/Bausch and Lomb | PII | Nitric oxide donating PGF2α agonist; NicOx and Bausch and Lomb partner in 2010 |
| Taprenepag isopropyl; PF-04217329 | Pfizer | PII | EP2 agonist |
Abbreviations: siRNA, small interfering RNA.